Innoviva, Inc. INVA
NASDAQ · United States · Health Technology
$20.55-0.66 (-3.11%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
BURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:
WALTHAM, Mass., August 11, 2026--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics produ
Innoviva, Inc. reported second-quarter 2026 results showing revenue of US$119.59 million, up from US$100.28 million a year earlier, but it moved from a net income of US$63.69 million to a net loss of US$83.42 million. Alongside these mixed earnings, Innoviva completed a substantial share repurchase under its November 2025 authorization, buying back 3,055,966 shares for US$66.40 million, which may reshape how investors view its capital allocation priorities. We’ll now examine how Innoviva’s...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.